Mounjaro Cost in Massachusetts 2026

What Does Mounjaro Actually Cost in Massachusetts?

Mounjaro's wholesale acquisition cost (WAC) is approximately $1,023 per month regardless of dose, because Eli Lilly prices all seven pen strengths at the same monthly WAC. Cash-pay patients at Massachusetts retail pharmacies, including CVS, Walgreens, and Walmart Pharmacy locations, will generally see prices ranging from $980 to $1,050 per fill for a four-pen box. GoodRx and SingleCare coupons occasionally pull this below $950, though availability varies by zip code and changes weekly.

That cash price is prohibitive for most patients. The practical cost depends almost entirely on three variables: whether you have commercial insurance that covers the drug, whether you qualify for the Eli Lilly savings program, and whether a compounded alternative fits your clinical situation.

Eli Lilly Savings Card

Eli Lilly's current savings card for Mounjaro lets eligible commercially insured patients pay as little as $25 per month. The card covers up to $150 in out-of-pocket costs per fill. Patients without any insurance coverage may qualify for Lilly's Insulin Value Program or patient assistance pathway, though Mounjaro-specific uninsured savings are more restricted. You can enroll directly at LillyDirect, and the card is accepted at most Massachusetts retail pharmacies. [1]

GoodRx and Pharmacy Coupons

GoodRx, RxSaver, and Blink Health coupons are available for tirzepatide but cannot be combined with insurance or the Lilly savings card. For uninsured Massachusetts patients who do not qualify for manufacturer assistance, these coupons represent the only discount layer on the $1,023 list price. The savings are modest, typically bringing the cost to $940 to $990 per month.

Price by Dose Strength

Because Eli Lilly uses flat monthly WAC pricing, a 2.5 mg starter pen box and a 15 mg maintenance box cost the same $1,023 per month. This is different from insulin pricing structures and means there is no financial incentive to stay at a lower dose once titration is medically appropriate.

Does Insurance Cover Mounjaro in Massachusetts?

Coverage depends on whether the prescription is written for type 2 diabetes (the FDA-approved indication) or for obesity or weight management (an off-label use for Mounjaro; for the obesity indication, the brand is Zepbound). Tirzepatide's efficacy data from SURPASS-2 (N=1,879) showed a mean HbA1c reduction of 2.01 percentage points at 40 weeks for the 15 mg dose versus 0.86 percentage points for semaglutide 1 mg, published in the New England Journal of Medicine. [2]

Commercial Plans

Most large commercial plans operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan, cover tirzepatide for type 2 diabetes under Tier 3 or Tier 4 formulary placement. Prior authorization is standard across all three and typically requires:

• Documented HbA1c of 7.0% or higher at the time of prescribing
• Failure of or contraindication to at least one first-line agent (usually metformin)
• Prescriber attestation of the type 2 diabetes diagnosis

Out-of-pocket cost after approval ranges from $50 to $200 per month depending on plan deductible status and tier structure. Patients in the deductible phase of a high-deductible health plan (HDHP) may pay the full negotiated rate, which is usually $700 to $850 per month, until the deductible is met.

Employer Self-Insured Plans

Approximately 60% of Massachusetts workers with employer coverage are in self-insured plans regulated by ERISA rather than state insurance law. These plans set their own formulary rules. Some have excluded GLP-1 agonists for weight loss entirely while maintaining diabetes coverage. Others have added Zepbound (tirzepatide for obesity) as a covered benefit in 2025 and 2026 following the American Diabetes Association's Standards of Medical Care in Diabetes 2024 position on obesity pharmacotherapy. [3]

Medicare Part D

Medicare Part D plans in Massachusetts cover Mounjaro for type 2 diabetes, though formulary placement varies by plan. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective January 1, 2025, limits maximum yearly exposure for Medicare beneficiaries. Monthly cost after the cap is reached is $0. Before the cap, expect Tier 3 or Tier 4 cost-sharing of $100 to $200 per fill depending on plan.

MassHealth (Massachusetts Medicaid) Coverage for Tirzepatide

MassHealth covers Mounjaro (tirzepatide) for the treatment of type 2 diabetes with prior authorization. The program does not currently cover tirzepatide for obesity or weight management as a standalone indication. Patients must meet MassHealth's preferred drug list (PDL) criteria, which generally mirror commercial PA requirements. [4]

Prior Authorization Criteria for MassHealth

MassHealth PA for tirzepatide typically requires:

• A confirmed diagnosis of type 2 diabetes (ICD-10 E11.x)
• HbA1c at or above 7.5% at initiation
• Documentation that metformin has been tried and is either ineffective or not tolerated
• Prescriber specialty note if the prescribing clinician is not an endocrinologist or primary care physician

The PA approval period is generally 12 months, with renewal requiring documented HbA1c improvement or clinical justification for continuation.

MassHealth for Weight Loss

MassHealth does not list tirzepatide on its obesity pharmacotherapy formulary as of January 2026. Patients seeking coverage specifically for weight management through MassHealth should ask their provider about appealing through the medical necessity exception process, citing the FDA's November 2023 approval of Zepbound (tirzepatide) for chronic weight management and their individual clinical circumstances. [5]

Is Compounded Tirzepatide Legal in Massachusetts?

Yes. Compounded tirzepatide from a licensed 503A pharmacy is legal in Massachusetts under current Massachusetts Board of Registration in Pharmacy regulations, as long as the compounding pharmacy holds an active state license and the prescription is issued by a licensed prescriber for an individual patient. [6]

503A vs. 503B Pharmacies

The distinction matters for patients and prescribers alike. A 503A pharmacy compounds for individual patients based on a valid prescription. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and is registered with the FDA rather than just licensed at the state level. Massachusetts has both. The FDA's guidance on compounded drug products makes clear that 503A compounds require a patient-specific prescription. [7]

Federal Shortage Status and Its Effect on Legality

Compounded tirzepatide was widely available in 2024 and early 2025 because the FDA listed tirzepatide on its drug shortage database, allowing broader compounding under shortage exemptions. The FDA removed tirzepatide from the shortage list in March 2025, which means:

• 503A pharmacies may still compound tirzepatide for individual patients with a valid prescription and a specific clinical need (e.g., documented allergy to a Mounjaro pen component or a need for a non-standard dose).
• 503B outsourcing facilities are no longer permitted to produce large-scale compounded tirzepatide batches now that the shortage has resolved.

Massachusetts 503A pharmacies operating in compliance with state board rules can therefore still fill compounded tirzepatide prescriptions in 2026, but the prescriber must document the clinical reason for compounding rather than dispensing the branded product.

Cost of Compounded Tirzepatide in Massachusetts

Licensed 503A compounding pharmacies in Massachusetts and partner pharmacies shipping legally into the state price compounded tirzepatide at approximately $199 to $249 per month for a standard 2.5 mg to 5 mg starting dose. Higher titration doses (10 mg to 15 mg equivalent) may cost $280 to $350 per month. These prices are all cash-pay; insurance does not cover compounded versions of FDA-approved drugs.

The HealthRX clinical team uses the following decision framework when evaluating whether a Massachusetts patient should pursue branded Mounjaro versus compounded tirzepatide in 2026:

1. Commercial insurance with diabetes PA approval. Use branded Mounjaro with the Lilly savings card. Out-of-pocket cost is $25 to $50 per month after the card.
2. MassHealth with type 2 diabetes. Pursue the PA process. Approval rates are high when criteria are met.
3. Uninsured or underinsured, no PA pathway. Compounded 503A tirzepatide from a Massachusetts-licensed pharmacy is the most cost-accessible option, typically $249 per month.
4. Commercial insurance, weight-loss indication only. Check whether your plan covers Zepbound (the FDA-approved obesity formulation). If not, compounded tirzepatide or the Zepbound savings card ($550 per month list, $25 with savings card for eligible patients) are the primary options.

Telehealth Access to Mounjaro in Massachusetts

Massachusetts allows telehealth prescribing of controlled and non-controlled prescription drugs, including Mounjaro, for patients with an established provider-patient relationship. The state amended its telehealth prescribing laws during the COVID-19 public health emergency and retained most of those provisions permanently. A prescriber licensed in Massachusetts may write a tirzepatide prescription after a synchronous video visit without a prior in-person exam, provided they conduct a clinically appropriate assessment. [8]

Telehealth Platforms Operating in Massachusetts

Several national telehealth platforms prescribe Mounjaro and compounded tirzepatide to Massachusetts residents, including:

• HealthRX (direct evaluation by a board-certified provider, with pharmacy coordination for 503A compounds or branded Mounjaro depending on insurance status)
• Ro
• Hims and Hers Health
• Noom Med

Telehealth visits for GLP-1 prescriptions typically cost $100 to $200 for an initial consultation. Ongoing monthly management fees range from $0 to $99 depending on the platform.

What a Massachusetts Telehealth GLP-1 Visit Covers

A compliant Massachusetts telehealth evaluation for Mounjaro should include:

• Review of current medications and contraindications (pancreatitis history, personal or family history of medullary thyroid carcinoma, MEN2)
• Fasting labs or review of recent HbA1c and metabolic panel
• BMI calculation and weight history
• Documentation of prior treatment attempts
• Shared decision-making about branded versus compounded options

Prescribers who skip this assessment and issue prescriptions after a brief questionnaire alone may not meet Massachusetts standard-of-care requirements for prescribing.

Clinical Evidence Supporting Tirzepatide Prescribing

Tirzepatide's approval for type 2 diabetes rests primarily on the SURPASS trial program. In SURPASS-2 (N=1,879), patients randomized to tirzepatide 15 mg achieved a mean HbA1c reduction of 2.01 percentage points from baseline and a mean body weight reduction of 11.9 kg at 40 weeks, compared with 0.86 percentage points and 3.1 kg for semaglutide 1 mg (P<0.001 for both). [2]

For obesity, the SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean weight reduction of 20.9% from baseline at 72 weeks versus 3.1% with placebo. These results were published in the New England Journal of Medicine and supported the November 2023 FDA approval of Zepbound. [9]

Dual GIP and GLP-1 Mechanism

Tirzepatide acts on both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. This dual mechanism produces greater glycemic control and weight loss than GLP-1-only agonists like semaglutide at approved doses, according to the FDA-approved prescribing information for Mounjaro. [1]

Side Effect Profile

The most common adverse effects in SURPASS-2 were gastrointestinal: nausea (17.4% at 15 mg), diarrhea (13.2%), and vomiting (9.7%). These effects were dose-dependent and generally resolved within the first four to eight weeks of treatment. The FDA prescribing label carries a black-box warning for thyroid C-cell tumors based on rodent data; the clinical relevance in humans is not established but patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use tirzepatide. [1]

How to Get the Lowest Possible Price in Massachusetts

Several strategies reduce cost in practice. None of them requires extraordinary effort once you know the system.

Step 1: Confirm Your Insurance Formulary Status

Call the member services number on your insurance card and ask specifically: "Is tirzepatide covered on my formulary for type 2 diabetes, and what tier is it?" Get the PA criteria in writing if possible. The answer takes about 10 minutes and determines whether you pursue the commercial PA route or the cash-pay route.

Step 2: Apply for the Lilly Savings Card Before Your First Fill

The Eli Lilly savings card is processed at the pharmacy counter the same as an insurance card. Enroll online before your prescription is sent to the pharmacy. The $25 minimum monthly cost applies as long as you have commercial insurance, including individual marketplace plans purchased through the Massachusetts Health Connector.

Step 3: Check MassHealth Eligibility

Massachusetts has one of the highest Medicaid eligibility thresholds in the country. Adults up to 133% of the federal poverty level qualify for MassHealth Standard. If your income has changed recently, a quick eligibility check at mahix.org takes under 15 minutes and could result in $0 monthly drug costs after PA approval.

Step 4: Evaluate Compounded Tirzepatide as a Bridge

If you are waiting for PA approval or cannot afford the list price while your deductible resets in January, a licensed 503A compounding pharmacy can fill tirzepatide at $249 per month. This keeps patients on therapy during coverage gaps. Your prescriber must document a clinical reason for the compound rather than the branded product.

Step 5: Consider Zepbound If Your Indication Is Obesity

Zepbound (tirzepatide for obesity) launched in late 2023 and has its own savings card. The FDA approved Zepbound on November 8, 2023, for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. [5] Commercially insured patients with obesity coverage may find Zepbound coverage easier to obtain than Mounjaro for weight loss, since Zepbound carries the on-label indication.

Massachusetts-Specific Regulations Prescribers and Patients Should Know

The Massachusetts Board of Registration in Medicine requires prescribers to maintain an adequate patient record before issuing prescriptions through telehealth, consistent with standards set by the Federation of State Medical Boards' Model Policy on Telemedicine. Massachusetts does not require an in-person visit before a telehealth prescribing encounter for non-controlled substances, and tirzepatide is not a controlled substance. [8]

The Massachusetts Board of Registration in Pharmacy audits 503A compounding pharmacies for compliance with USP <797> sterile compounding standards, which apply to injectable tirzepatide preparations. Patients using compounded tirzepatide should verify their pharmacy's current Massachusetts license status at the Massachusetts Division of Professional Licensure lookup tool.

The American Association of Clinical Endocrinology (AACE) 2023 Clinical Practice Guideline for obesity pharmacotherapy recommends GIP/GLP-1 dual agonists as preferred agents for patients with obesity and type 2 diabetes, citing superior HbA1c and weight outcomes compared with GLP-1-only agents. [10]